Artificial intelligence and its expanding role across the biopharma landscape

Artificial intelligence (AI) is already a well-established tool across biopharma. Since most Al adoption has been in research and development, as opposed to downstream commercial operations, there are still substantial opportunities for increased integration. In addition, organizations are actively exploring how to layer generative Al, including large language models (LLMs) like OpenAl's ChatGPT, on top of existing data and Al models to further bolster the drug discovery process and augment operations.

This paper provides an overview of key trends that demonstrate Al's staying power in the biopharma industry. These include top 10 biopharmas' investment strategies and adoption of Al to enhance existing capabilities or bolster pipeline activities. We evaluated the expanding landscape of biopharma company models, with an emphasis on Al-focused entities in the pharmaceutical and service spaces. Further, we seek to shed light on the pivotal factors affecting the acceptance and integration of these innovative paradigms by the wider biopharma community.